Use of dexmedetomidine in complex treatment of patients in intensive care units

Authors

  • Dmytro Dmytriiev National Pirogov Memorial Medical University, Vinnytsia
  • Oleksandr Nazarchuk National Pirogov Memorial Medical University, Vinnytsia
  • Yuliana Babina National Pirogov Memorial Medical University, Vinnytsia

DOI:

https://doi.org/10.31636/prmd.v5i1.1

Keywords:

sedation, dexmedetomidine, mechanical ventilation, non-invasive ventilation, COVID-19

Abstract

Sedation is an important aspect of adequate treatment of patients in the intensive care unit. Recent drug developments and new ventilation strategies provide improved sedation management that allows for better adaptation to the clinical condition and individual needs of the patient. This article provides an overview of the general principles of sedation of patients in intensive care units and focuses on a relatively new drug in the pharmaceutical market of Ukraine — dexmedetomidine. Given the pandemic of coronavirus disease COVID-19, there was carried out a review of the international and domestic literature describing the use of dexmedetomidine as a sedative and analgesic in patients with acute respiratory distress syndrome caused by SARS-COV-2 virus. Its anti-inflammatory and antioxidant properties are also described, which will allow the use of the drug in complex therapy in the treatment of COVID-19 in severe patients.

Downloads

Download data is not yet available.

References

Fraser GL, Devlin JW, Worby CP, Alhazzani W, Barr J, Dasta JF, et al. Benzodiazepine Versus Nonbenzodiazepine-Based Sedation for Mechanically Ventilated, Critically Ill Adults. Critical Care Medicine [Internet]. Ovid Technologies (Wolters Kluwer Health); 2013 Sep;41:S30–S38. Available from: https://doi.org/10.1097/ccm.0b013e3182a16898

Belda JF, Soro M, Badenes R, Meiser A, García ML, Aguilar G, et al. The Predictive Performance of a Pharmacokinetic Model for Manually Adjusted Infusion of Liquid Sevofluorane for Use with the Anesthetic-Conserving Device (AnaConDa): A Clinical Study. Anesthesia & Analgesia [Internet]. Ovid Technologies (Wolters Kluwer Health); 2008 Apr;106(4):1207–14. Available from: https://doi.org/10.1213/ane.0b013e31816782ff

Potievskaya VI, Gritchik IE, Gritsan AI, Eremenko AA, Zabolotskikh IB, Kozlov IA, Lebedinsky KM, Levit AL, Mazurok VA, Molchanov IV, Nikolaenko EM. Sedation of patients in intensive care units and intensive care units [Sedatsiya patsiyentov v otdeleniyakh reanimatsii i intensivnoy terapii]. Anesthesiology and resuscitation. 2018;63(2):165-75. [In Russian]

Ovechkin AM. Analgesia and sedation in intensive care [Anal'geziya i sedatsiya v intensivnoy terapii]. Bulletin of Intensive Care. 2009(1):21-6. [In Russian]

Dawson R, Fintel N von, Nairn S. Sedation assessment using the Ramsay scale. Emergency Nurse [Internet]. RCN Publishing Ltd.; 2010 Jun 9;18(3):18–20. Available from: https://doi.org/10.7748/en2010.06.18.3.18.c7825

Rasheed AM, Amirah MF, Abdallah M, P.J. P, Issa M, Alharthy A. Ramsay Sedation Scale and Richmond Agitation Sedation Scale. Dimensions of Critical Care Nursing [Internet]. Ovid Technologies (Wolters Kluwer Health); 2019;38(2):90–5. Available from: https://doi.org/10.1097/dcc.0000000000000346

Whipple JK, Lewis KS, Quebbeman EJ, Wolff M, Gottlieb MS, Medicus‐Bringa M, Hartnett KR, Graf M, Ausman RK. Analysis of pain management in critically ill patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1995 Sep 10;15(5):592-9. Available from: https://doi.org/10.1002/j.1875-9114.1995.tb02868.x

International association for the study of pain. IASP statement on opioids. 2018.

Martin J, Heymann A, Bäsell K, Baron R, Biniek R, Bürkle H, Dall P, Dictus C, Eggers V, Eichler I, Engelmann L. Evidence and consensus-based German guidelines for the management of analgesia, sedation and delirium in intensive care–short version. GMS German Medical Science. 2010;8. Available from: https://dx.doi.org/10.3205/000091

Belyshev SYu, Levit AL. Sedation in intensive care. Review of the current state of the problem [Sedatsiya v intensivnoy terapii. Obzor sovremennogo sostoyaniya problemy]. General resuscitation. 2012;8(3):56-62. [In Russian]

Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica MF, Bjerke HS, Coplin WM, Crippen DW. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Critical care medicine. 2002 Jan 1;30(1):119-41. Available from: https://doi.org/10.1097/00003246-200201000-00020

Sigler M, Islam E, Nugent K. Comparison of dexmedetomidine and propofol in mechanically ventilated patients with sepsis: A pilot study. The Southwest Respiratory and Critical Care Chronicles [Internet]. The Southwest Respiratory and Critical Care Chronicles (SWRCCC); 2018 Jan 19;6(22):10–5. Available from: https://doi.org/10.12746/swrccc.v6i22.444

Keating GM. Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting. Drugs [Internet]. Springer Science and Business Media LLC; 2015 Jun 11;75(10):1119–30. Available from: https://doi.org/10.1007/s40265-015-0419-5

Dmytriiev D, Bortnik D, Rudnitsky Y, Heranin S, Korenchuk N. Dexmedetomidine for sedation in intensive care. Literature review and clinical experience. Perioperaciina Medicina [Internet]. Interdisciplinar Academy of Pain Medicine; 2020 Jun 1;3(1):33–9. Available from: https://doi.org/10.31636/prmd.v3i1.6

Czepiel KS, Lucas AT, Whalen MJ, Mojica JE. Dexmedetomidine-Associated Hyperpyrexia in Three Critically Ill Patients With Coronavirus Disease 2019. Critical Care Explorations [Internet]. Ovid Technologies (Wolters Kluwer Health); 2020 Sep;2(9):e0213. Available from: https://doi.org/10.1097/cce.0000000000000213

Romera Ortega MA, Chamorro Jambrina C, Lipperheide Vallhonrat I, Fernández Simón I. Indicaciones de la dexmedetomidina en las tendencias actuales de sedoanalgesia en el paciente crítico. Medicina Intensiva [Internet]. Elsevier BV; 2014 Jan;38(1):41–8. Available from: https://doi.org/10.1016/j.medin.2013.03.008

Reel B, Maani CV. Dexmedetomidine. StatPearls Treasure Island (FL): StatPearls Publishing. 2020; [Internet].

Panharipande PP, Pun BT, Herr D. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients. JAMA. 2007;298(22):2644-53. Available from: https://doi.org/10.1001/jama.298.22.2644

Romera Ortega MA, Chamorro Jambrina C, Lipperheide Vallhonrat I, Fernández Simón I. Indications of dexmedetomidine in the current sedoanalgesia trends in the critical patient. Medicina Intensiva (English Edition) [Internet]. Elsevier BV; 2014 Jan;38(1):41–8. Available from: https://doi.org/10.1016/j.medine.2013.03.003

Ruokonen E, Parviainen I, Jakob SM, Nunes S, Kaukonen M, et al. Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation. Intensive Care Medicine [Internet]. Springer Science and Business Media LLC; 2008 Sep 16;35(2):282–90. Available from: https://doi.org/10.1007/s00134-008-1296-0

Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, Bratty JR, Takala J, Dexmedetomidine for Long-Term Sedation Investigators. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. Jama. 2012 Mar 21;307(11):1151-60. Available from: https://doi.org/10.1001/jama.2012.304

Hsu YW, Cortinez LI, Robertson KM, Keifer JC, Sum-Ping ST, Moretti EW, Young CC, Wright DR, MacLeod DB, Somma J. Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. The Journal of the American Society of Anesthesiologists. 2004 Nov 1;101(5):1066-76. Available from: https://doi.org/10.1097/00000542-200411000-00005

Hanidziar D, Bittner EA. Sedation of Mechanically Ventilated COVID-19 Patients: Challenges and Special Considerations. Anesthesia & Analgesia [Internet]. Ovid Technologies (Wolters Kluwer Health); 2020 Apr 15;131(1):e40–e41. Available from: https://doi.org/10.1213/ane.0000000000004887

Zazzara MB, Penfold RS, Roberts AL, Lee KA, Dooley H, Sudre CH, et al. Delirium is a presenting symptom of COVID-19 in frail, older adults: a cohort study of 322 hospitalised and 535 community-based older adults. Cold Spring Harbor Laboratory; 2020 Jun 17; Available from: https://doi.org/10.1101/2020.06.15.20131722

Reade MC, O’Sullivan K, Bates S, Goldsmith D, Ainslie WR, Bellomo R. Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Critical Care [Internet]. Springer Science and Business Media LLC; 2009;13(3):R75. Available from: https://doi.org/10.1186/cc7890

Zhao H, Davies R, Ma D. Potential therapeutic value of dexmedetomidine in COVID-19 patients admitted to ICU. British Journal of Anaesthesia [Internet]. Elsevier BV; 2021 Jan;126(1):e33–e35. Available from: https://doi.org/10.1016/j.bja.2020.09.031

Reel B; Maani CV. Dexmedetomidine. In: StatPearls [Internet]. StatPearls Publishing; 2019.

Koyyalamudi V, Sen S, Patil S, Creel JB, Cornett EM, Fox CJ, Kaye AD. Adjuvant agents in regional anesthesia in the ambulatory setting. Current pain and headache reports. 2017 Jan;21(1):6. Available from: https://doi.org/10.1007/s11916-017-0604-1

Correction to: Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation [Internet]. Ovid Technologies (Wolters Kluwer Health); 2016 Sep 20;134(12):e261. Available from: https://doi.org/10.1161/cir.0000000000000449

Використання дексмедетомідину в комплексному  лікуванні пацієнтів у відділеннях інтенсивної терапії

Published

2022-05-30

How to Cite

1.
Dmytriiev D, Nazarchuk O, Babina Y. Use of dexmedetomidine in complex treatment of patients in intensive care units. prmd [Internet]. 2022 May 30 [cited 2022 Jul. 1];5(1):4-10. Available from: https://perioperative.org.ua/index.php/prtmdc/article/view/99

Issue

Section

Problem article

Most read articles by the same author(s)

1 2 > >>